Vascular Solutions, Inc. (VASC) Tops Q2 EPS by 2c; Guides

Vascular Solutions, Inc. (NASDAQ: VASC) reported Q2 EPS of $0.20, $0.02 better than the analyst estimate of $0.18. Revenue for the quarter came in at $30.7 million versus the consensus estimate of $30.43 million.

Vascular Solutions, Inc. sees FY2014 GAAP EPS of $0.73-$0.77, which may note compare to the consensus of $0.72. Vascular Solutions, Inc. sees FY2014 revenue of $123-125 million, versus prior guidance of $121-125 million and the consensus of $122.22 million.

"During the second quarter, we again achieved a record level of quarterly revenue while sustaining double-digit revenue growth," said Howard Root, Chief Executive Officer of Vascular Solutions. "Even though we continue to incur substantial legal expenses related to our intellectual property litigation with Boston Scientific and our response to the government criminal investigation of our Vari-Lase® Short Kit product, we continue to improve our operating margins. We are very pleased to be on our way toward delivering our 11th consecutive year of double-digit revenue growth while continuing to grow our profitability and investing heavily for our future growth and sustaining our pace of new product innovation."

For earnings history and earnings-related data on Vascular Solutions, Inc. (VASC) click here.

You May Also Be Interested In

• Charles Schwab (SCHW) EPS edges past estimates, revenue up sequentially but dips YoY
• Goldman Sachs (GS) tops Q1 earnings, revenue expectations
• Goldman Sachs (GS) Tops Q1 EPS by $2.84